Scoped author-reported evidence candidate; no clinical recommendation.
These checks assess whether the evidence supports a reproducible investigation. A source-checked score alone does not meet these requirements.
Release 2026-10-07-1448159e6a81 · Evidence verified: Not verified
Exact outcomes, predictions, identifiers and evaluator are connected.
Missing or unresolved evidence
Verified: Not verified
Replay evidence includes annotations and an assessment of dependence. Unknown independence permits descriptive analysis only.
Missing or unresolved evidence
Verified: Not verified
A pinned recipe describes the inputs, environment and resource requirements.
Missing or unresolved evidence
Verified: Not verified
Separate data and exposure records support an independent test.
Missing or unresolved evidence
Verified: Not verified
Readiness describes the evidence in this release. Availability on your computer is checked separately when an investigation runs. Existing data exposure can prevent independent validation even when files are available.
No verified artifact manifest is connected to this record yet. The gaps above identify what is needed before analysis can begin.
1 evaluation · 1 result. Different protocols are not a single leaderboard.
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Configuration: cfMethyl-Seq stacked ensemble (2022) | Protocol: cfMethyl-Seq random-split four-cancer detection Dataset: cfMethyl-Seq 408 QC-passing plasma samples | 80.7% sensitivity_at_97_9_percent_specificity percent · higher Uncertainty: 95% CI 68.6%–90.7% Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcecfMethyl-Seq all-stage cancer detection amp-protocol-cfmethyl-randomsplit-detection Aggregation: Not reported cfMethyl-Seq cancer detection primary paper · PMC9522828 XML Par17, Results Cancer detection, Fig3a; split Par16; configuration Par37 |
Source checking is not independent reproduction. Release 2026-10-07-1448159e6a81.
A dataset supplies biological observations. The evaluation protocol defines how those observations are split, used and scored.
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
8 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
| attributes.access EGA EGAS00001006020; corresponding-author request; restricted to non-commercial entities Context-only references | cfMethyl-Seq cancer detection primary paper XML Par16, Par34, Fig3 caption, Data availability Version: 2022 version of record, corrected competing-interest disclosure in 2024 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.assay Plasma cfDNA methylome, cfMethyl-Seq, 150bp paired-end Illumina; UMI removal, Trim-galore, Bismark alignment to hg19/GRCh37 GCA000001405.1, Umi-Grinder deduplication Context-only references | cfMethyl-Seq cancer detection primary paper XML Par16, Par34, Fig3 caption, Data availability Version: 2022 version of record, corrected competing-interest disclosure in 2024 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.population 217 cancers (49 colon, 30 liver, 106 lung, 32 stomach), 191 noncancers, from 479 generated libraries; 408 pass coverage >15x and conversion >98.7% QC. Of remaining 75% noncancer, 30 reserved solely for marker discovery. Fig 3c labels test n=102; per-split cancer/noncancer integer counts unreported. Context-only references | cfMethyl-Seq cancer detection primary paper XML Par16, Par34, Fig3 caption, Data availability Version: 2022 version of record, corrected competing-interest disclosure in 2024 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.source_locator XML Par16, Par34, Fig3 caption, Data availability Context-only references | cfMethyl-Seq cancer detection primary paper XML Par16, Par34, Fig3 caption, Data availability Version: 2022 version of record, corrected competing-interest disclosure in 2024 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.split 10 repeated random 75:25 train/test splits Context-only references | cfMethyl-Seq cancer detection primary paper XML Par16, Par34, Fig3 caption, Data availability Version: 2022 version of record, corrected competing-interest disclosure in 2024 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.version 2022 paper cohort Context-only references | cfMethyl-Seq cancer detection primary paper XML Par16, Par34, Fig3 caption, Data availability Version: 2022 version of record, corrected competing-interest disclosure in 2024 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| description Scoped author-reported evidence candidate; no clinical recommendation. Context-only references | cfMethyl-Seq cancer detection primary paper XML Par16, Par34, Fig3 caption, Data availability Version: 2022 version of record, corrected competing-interest disclosure in 2024 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| name cfMethyl-Seq 408 QC-passing plasma samples Context-only references | cfMethyl-Seq cancer detection primary paper XML Par16, Par34, Fig3 caption, Data availability Version: 2022 version of record, corrected competing-interest disclosure in 2024 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
View linked audit checks and correction history
Release 2026-10-07-1448159e6a81 · Record review: source checked
Stable ID: amp-data-cfmethyl-408